Clinical Study
Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma
Table 1
Baseline clinical characteristics of patients.
| | | Number of patients | % |
| | Sex | | | | M | 48 | 96 | | F | 2 | 4 | | Median age at diagnosis (year) | 52 (range: 30–75) | | | Hepatitis history | | | | HBV infection | 32 | 64 | | HCV infection | 4 | 8 | | HBV + HCV | 11 | 22 | | Non-B, non-C | 3 | 6 | | Liver cirrhosis | | | | Yes | 39 | 78 | | No | 11 | 22 | | Previous hepatectomy | | | | Yes | 8 | 16 | | No | 42 | 84 | | Previous local treatment | | | | 0 | 20 | 40 | | 1 | 10 | 20 | | 2 | 17 | 34 | | 3 | 3 | 6 | | Previous systemic treatment | | | | 0 | 43 | 86 | | 1 | 6 | 12 | | 2 | 1 | 2 | | Child-Pugh class at IA chemotherapy | | | | A | 42 | 84 | | B | 6 | 12 | | C | 2 | 4 | | BCLC stage at IA chemotherapy | | | | B | 8 | 16 | | C | 32 | 64 | | D | 10 | 20 | | Indication for IA chemotherapy | | | | PVT | 24 | 48 | | Multiple nodules | 13 | 26 | | TAE failure | 7 | 14 | | Extrahepatic metastasis | 6 | 12 | | Pretreatment laboratory data, median (range) | | | | Bilirubin (mg/dL) | | 1.0 (0.4–2.0) | | Albumin (g/dL) | | 3.4 (1.8–4.3) | | Platelet count (/uL) | | 165 (54–589) | | ALT (IU/L) | | 46 (16–184) | | INR of prothrombin time | | 1.09 (0.93–1.33) | | -fetoprotein (ng/mL) | | 307.9 (3–>87,500) |
|
|
ALT: alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; HBV: hepatitis B virus; HCV: hepatitis C virus; IA: intraarterial; INR: international normalized ratio; PVT: portal vein thrombosis; TAE: transarterial embolization.
Local treatments included transarterial embolization, alcohol injection, and radiofrequency ablation.
Systemic treatments included chemotherapy, thalidomide, and targeted therapies.
|
